MCID: HYP056
MIFTS: 65

Hypoglycemia

Categories: Blood diseases, Endocrine diseases, Metabolic diseases

Aliases & Classifications for Hypoglycemia

MalaCards integrated aliases for Hypoglycemia:

Name: Hypoglycemia 12 74 29 54 6 42 44 15 71
Hypoglycaemia 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:9993
ICD9CM 34 251.2
MeSH 44 D007003
NCIt 50 C3126
SNOMED-CT 67 154691006
ICD10 32 E16.2
UMLS 71 C0020615

Summaries for Hypoglycemia

MedlinePlus : 42 Hypoglycemia means low blood glucose, or blood sugar. Your body needs glucose to have enough energy. After you eat, your blood absorbs glucose. If you eat more sugar than your body needs, your muscles, and liver store the extra. When your blood sugar begins to fall, a hormone tells your liver to release glucose. In most people, this raises blood sugar. If it doesn't, you have hypoglycemia, and your blood sugar can be dangerously low. Signs include Hunger Shakiness Dizziness Confusion Difficulty speaking Feeling anxious or weak In people with diabetes, hypoglycemia is often a side effect of diabetes medicines. Eating or drinking something with carbohydrates can help. If it happens often, your health care provider may need to change your treatment plan. You can also have low blood sugar without having diabetes. Causes include certain medicines or diseases, hormone or enzyme deficiencies, and tumors. Laboratory tests can help find the cause. The kind of treatment depends on why you have low blood sugar. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hypoglycemia, also known as hypoglycaemia, is related to hyperinsulinemic hypoglycemia, familial, 2 and hyperinsulinemic hypoglycemia, familial, 7, and has symptoms including sugar craving An important gene associated with Hypoglycemia is G6PC1 (Glucose-6-Phosphatase Catalytic Subunit 1), and among its related pathways/superpathways are Metabolism and PI3K-Akt signaling pathway. The drugs Pramlintide and Glyburide have been mentioned in the context of this disorder. Affiliated tissues include pancreas, pituitary and liver, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A glucose metabolism disease that is characterized by abnormally low levels of blood glucose.

Wikipedia : 74 Hypoglycemia, also known as low blood sugar, is a fall in blood sugar to levels below normal. This may... more...

Related Diseases for Hypoglycemia

Diseases related to Hypoglycemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1126)
# Related Disease Score Top Affiliating Genes
1 hyperinsulinemic hypoglycemia, familial, 2 33.4 KCNJ11 INS ABCC8
2 hyperinsulinemic hypoglycemia, familial, 7 33.0 SLC16A1 KCNJ11 HADH GLUD1 GCK ABCC8
3 hyperinsulinemic hypoglycemia, familial, 6 32.9 SLC16A1 KCNJ11 HADH GLUD1 GCK ABCC8
4 hyperinsulinemic hypoglycemia, familial, 4 32.7 INSR HADH
5 hyperinsulinemic hypoglycemia 32.6 SLC16A1 KCNJ11 INSR INS IGF2 HADH
6 carnitine palmitoyltransferase ii deficiency, infantile 32.5 SLC25A20 HADH ACADVL ACADM ACADL
7 type 1 diabetes mellitus 32.3 INSR INS IGF2 GCK GCG
8 glycogen storage disease ia 32.3 INS GCG G6PC1 FBP1
9 fructose-1,6-bisphosphatase deficiency 32.3 GCK GCG G6PC1 FBP1 ABCC8
10 fasting hypoglycemia 32.3 INSR IGF2 GYS2 GLUD1 CRH ACADM
11 mitochondrial trifunctional protein deficiency 32.2 SLC25A20 HADH ACADVL ACADM
12 long-chain 3-hydroxyacyl-coa dehydrogenase deficiency 32.1 HADH ACADVL ACADM
13 beckwith-wiedemann syndrome 32.1 KCNJ11 INS IGF2 ABCC8
14 carnitine deficiency, systemic primary 32.1 SLC25A20 HADH ACADVL ACADM
15 acyl-coa dehydrogenase, very long-chain, deficiency of 32.0 SLC25A20 HADH ACADVL ACADM ACADL
16 acyl-coa dehydrogenase, medium-chain, deficiency of 32.0 SLC25A20 HADH ACADVL ACADM ACADL
17 3-hydroxyacyl-coa dehydrogenase deficiency 32.0 HADH GLUD1 GCK ACADVL ACADM
18 multiple acyl-coa dehydrogenase deficiency 32.0 SLC25A20 HADH ACADVL ACADM
19 epiphyseal dysplasia, multiple, with early-onset diabetes mellitus 32.0 KCNJ11 INS ABCC8
20 hyperinsulinism 31.9 SLC16A1 KCNJ11 INSR INS IGF2 HADH
21 acyl-coa dehydrogenase, short-chain, deficiency of 31.9 HADH ACADVL ACADM
22 insulinoma 31.8 INS GCK GCG ABCC8
23 hyperglycemia 31.8 KCNJ11 INSR INS GCK GCG G6PC1
24 donohue syndrome 31.8 INSR INS GCK
25 islet cell tumor 31.6 INSR INS IGF2 GCG
26 hypoglycemic coma 31.5 INS IGF2 GCG
27 diabetes mellitus 31.3 KCNJ11 INSR INS IGF2 GCK GCG
28 diabetes mellitus, ketosis-prone 31.2 KCNJ11 INS GCG ABCC8
29 type 2 diabetes mellitus 31.2 KCNJ11 INSR INS IGF2 GYS2 GCK
30 glycogen storage disease 31.1 INS IGF2 GYS2 G6PC1
31 gestational diabetes 31.1 KCNJ11 INSR INS GCK GCG ABCC8
32 insulin-like growth factor i 31.1 INSR INS IGF2 AKT2
33 potter's syndrome 31.1 INS IGF2
34 neonatal diabetes 30.8 KCNJ11 INS GCK ABCC8
35 maturity-onset diabetes of the young 30.8 SLC16A1 KCNJ11 INS GCK GCG G6PC1
36 glucose intolerance 30.8 KCNJ11 INSR INS GCK GCG ABCC8
37 fetal macrosomia 30.7 INSR INS IGF2
38 acyl-coa dehydrogenase deficiency 30.7 ACADVL ACADM
39 factitious disorder 30.6 KCNJ11 INS GCK ABCC8
40 maturity-onset diabetes of the young, type 3 30.6 KCNJ11 INS GCK ABCC8
41 munchausen by proxy 30.6 KCNJ11 GCK ABCC8
42 pituitary gland disease 30.5 INS GCG CRH
43 asphyxia neonatorum 30.5 SLC16A1 KCNJ11 INS HADH ABCC8
44 monocarboxylate transporter 1 deficiency 30.5 SLC16A1 INS GLUD1
45 monogenic diabetes 30.4 KCNJ11 INS GCK ABCC8
46 maple syrup urine disease 30.4 SLC25A20 HADH GLUD1 ACADM
47 permanent neonatal diabetes mellitus 30.3 KCNJ11 INS GCK GCG ABCC8
48 sheehan syndrome 30.3 INS CRH
49 transient neonatal diabetes mellitus 30.3 KCNJ11 INS IGF2 GCK ABCC8
50 maturity-onset diabetes of the young, type 2 30.3 KCNJ11 INS GCK ABCC8

Comorbidity relations with Hypoglycemia via Phenotypic Disease Network (PDN): (show all 30)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Alzheimer Disease
Benign Essential Hypertension Bronchitis
Cerebral Atherosclerosis Decubitus Ulcer
Deficiency Anemia Diabetic Polyneuropathy
Encephalopathy Familial Atrial Fibrillation
First-Degree Atrioventricular Block Generalized Atherosclerosis
Heart Disease Hypertension, Essential
Hypoglycemic Coma Hypothyroidism
Intermediate Coronary Syndrome Iron Deficiency Anemia
Kidney Disease Microvascular Complications of Diabetes 1
Microvascular Complications of Diabetes 7 Mitral Valve Disease
Peripheral Vascular Disease Protein-Energy Malnutrition
Respiratory Failure Schizophreniform Disorder
Sinoatrial Node Disease Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Hypoglycemia:



Diseases related to Hypoglycemia

Symptoms & Phenotypes for Hypoglycemia

UMLS symptoms related to Hypoglycemia:


sugar craving

GenomeRNAi Phenotypes related to Hypoglycemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.72 AKT2 GCK INSR
2 Decreased viability GR00221-A-2 9.72 GCK INSR
3 Decreased viability GR00221-A-3 9.72 AKT2 GCK INSR
4 Decreased viability GR00221-A-4 9.72 AKT2 GCK INSR
5 Decreased viability GR00249-S 9.72 ACADM G6PC1 GCG HADH
6 Decreased viability GR00301-A 9.72 AKT2
7 Decreased viability GR00342-S-3 9.72 AKT2
8 Decreased viability GR00386-A-1 9.72 ACADL ACADM GCG SLC16A1
9 Decreased viability GR00402-S-2 9.72 ACADL ACADM ACADVL GLUD1

MGI Mouse Phenotypes related to Hypoglycemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.21 ABCC8 ACADL ACADM ACADVL AKT2 CRH
2 growth/size/body region MP:0005378 10.13 ABCC8 ACADVL AKT2 CRH G6PC1 GCK
3 endocrine/exocrine gland MP:0005379 10.11 ABCC8 AKT2 CRH GCK GLUD1 HADH
4 cardiovascular system MP:0005385 10.1 ACADL ACADM ACADVL GCK GYS2 IGF2
5 adipose tissue MP:0005375 10.03 ACADVL AKT2 CRH HADH INS INSR
6 liver/biliary system MP:0005370 9.97 ACADL ACADM ACADVL AKT2 CRH G6PC1
7 muscle MP:0005369 9.56 ACADM ACADVL AKT2 GYS2 IGF2 INS
8 renal/urinary system MP:0005367 9.28 ACADL CRH G6PC1 GCK HADH IGF2

Drugs & Therapeutics for Hypoglycemia

Drugs for Hypoglycemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 304)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pramlintide Approved, Investigational Phase 4 151126-32-8
2
Glyburide Approved Phase 4 10238-21-8 3488
3
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
4
Lixisenatide Approved Phase 4 320367-13-3
5
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
6
Verapamil Approved Phase 4 52-53-9 2520
7
Ofloxacin Approved Phase 4 82419-36-1 4583
8
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
9
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
10
Gliclazide Approved Phase 4 21187-98-4 3475
11
Insulin aspart Approved Phase 4 116094-23-6 16132418
12
Glucagon Approved Phase 4 16941-32-5
13
Pancrelipase Approved, Investigational Phase 4 53608-75-6
14
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
15
Empagliflozin Approved Phase 4 864070-44-0
16
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
17
Zinc Approved, Investigational Phase 4 7440-66-6 32051
18
Insulin detemir Approved Phase 4 169148-63-4 5311023
19
Insulin glargine Approved Phase 4 160337-95-1
20
Metformin Approved Phase 4 657-24-9 14219 4091
21
Glimepiride Approved Phase 4 93479-97-1 3476
22 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
23
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
24
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
25
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
26
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
27
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
28
gastric inhibitory polypeptide Investigational Phase 4 100040-31-1
29
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
30 Antineoplastic Agents, Hormonal Phase 4
31 glucocorticoids Phase 4
32 Insulin degludec, insulin aspart drug combination Phase 4
33 Cathartics Phase 4
34 Laxatives Phase 4
35 Insulin aspart, insulin aspart protamine drug combination 30:70 Phase 4
36 Biphasic Insulins Phase 4
37 Cardiac Glycosides Phase 4
38 Glycoside Hydrolase Inhibitors Phase 4
39 calcium channel blockers Phase 4
40 (1-6)-alpha-glucomannan Phase 4
41 Manna Phase 4
42 Insulin, Isophane Phase 4
43 Isophane Insulin, Human Phase 4
44 Isophane insulin, beef Phase 4
45 Glucagon-Like Peptide 1 Phase 4
46 Gastrointestinal Agents Phase 4
47 pancreatin Phase 4
48 Insulin, Short-Acting Phase 4
49 diuretics Phase 4
50 Mineralocorticoid Receptor Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 689)
# Name Status NCT ID Phase Drugs
1 Is Insulin NovoRapid Better Than Actrapid for Treating Type 1 Diabetic Patients When Simultaneously, Daily Adjusting the Insulin Dose? Unknown status NCT00145353 Phase 4 Insulin NovoRapid versus Actrapid
2 Impact of Insulin Detemir Versus Insulin Glargine on Glycaemic Control and Metabolism During Exercise in Type 1 Diabetes Unknown status NCT01440439 Phase 4 Insulin glargine;Insulin detemir
3 Do Sulphonylureas Preserve Cortical Function During Hypoglycaemia? Unknown status NCT00472875 Phase 4 Glibenclamide
4 Pasireotide in the Treatment of Hypoglycemia Following Gastric Bypass Surgery Unknown status NCT03514576 Phase 4 Pasireotide 0.3 MG/ML
5 Organization Program of DiabEtes INsulIN ManaGement: An Open, Multi-center, Prospective, Randomized, 16-week, Controlled Clinical Study Unknown status NCT01338376 Phase 4 Scilin®M30
6 Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery Unknown status NCT01841359 Phase 4 Pramlintide
7 Treatment of Hypoglycemia With Glucagon Among Patients With Type 1 Diabetes Mellitus Unknown status NCT02232971 Phase 4 Glucagon
8 The Effect of Insulin Analogues and Human Insulin on the Incidence of Severe Hypoglycaemia in Hypoglycaemia Prone Type 1 Diabetic Patients Completed NCT00346996 Phase 4 insulin levemir / aspart;human insulin /insulin isophane
9 Glycemic Excursions in Type 2 Diabetic Patients Treated With Vildagliptin and Metformin (GalvusMet) Versus Glimepiride and Metformin Completed NCT02007278 Phase 4 vildagliptin and metformin (combination);glimepiride;Metformin
10 Comparison of the Risk of Complications and the Quality of Life During Ramadan Fasting in Patients With Corticotrope Deficiency Treated Either by Hydrocortisone or by Prednisolone Completed NCT03585829 Phase 4 Hydrocortisone;Prednisolone
11 Continuous Subcutaneous Infusion of Pramlintide and Insulin: A Randomized, Crossover Design Study Completed NCT00291772 Phase 4 Pramlintide
12 Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes Treated With Basal Bolus Insulin Regimen Completed NCT02408120 Phase 4 Insulin glargine;Insulin aspart;Supplemental insulin aspart
13 Can Hypoglycaemia Awareness Be Restored in Individuals With Type 1 Diabetes and Severe Hypoglycaemia Employing Optimised Subcutaneous Insulin Regime or Continuous Subcutaneous Insulin Infusion Pump Completed NCT00360984 Phase 4 insulin glargine
14 A Phase IIIb/IV, Multinational, Multicentre, Randomised, Open Study to Establish the Optimal Method for Initiating and Maintaining Lantus® (Insulin Glargine) Therapy Based on a Comparison of Two Treatment Algorithms to Determine Optimal Metabolic Outcomes, Safety, and Satisfaction in Subjects With Type 1 Diabetes Mellitus/ "HALT" Sub-study: Multicentre, Open Clinical Trial to Assess the Effect of Insulin Glargine on Symptomatic Hypoglycaemia, Fear of Hypoglycaemia and Quality of Life in Patients With Type 1 Diabetes Completed NCT00390728 Phase 4 Insulin Glargine
15 The Effect of Insulin Degludec on Risk of Symptomatic Nocturnal Hypoglycaemia in Subjects With Type 1 Diabetes and High Risk of Nocturnal Severe Hypoglycaemia Completed NCT02192450 Phase 4 Insulin aspart/glargine;Insulin aspart/degludec
16 Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes Completed NCT02303730 Phase 4 Exenatide;insulin glargine
17 Use of Diazoxide in Acute Hypoglycaemia Completed NCT01488136 Phase 4 Diazoxide;Placebo
18 A Double-blind, Randomised, Crossover Study to Investigate the Difference in Frequency of Episodes of Hypoglycaemia During Treatment With Biphasic Insulin Aspart 30 Compared to Biphasic Human Insulin 30 in Patients With Well-controlled Type 2 Diabetes Completed NCT01487798 Phase 4 biphasic human insulin 30;biphasic insulin aspart 30
19 Sitagliptin for the Prevention and Treatment of Stress Hyperglycemia in Non-Diabetic Patients Undergoing Cardiac Surgery Completed NCT02443402 Phase 4 Sitagliptin;Placebo;Regular Human Insulin;Insulin glargine;Supplemental insulin (Insulin lispro);Supplemental insulin (Insulin aspart)
20 Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes Completed NCT02455076 Phase 4 Exenatide;Glargine;Rapid-acting insulin analogs
21 Prevention of Stress Hyperglycemia With the Use of DPP-4 Inhibitors in Non-diabetic Patients Undergoing Non-cardiac Surgery, a Pilot Study Completed NCT02741687 Phase 4 Sitagliptin;Placebo;Supplemental insulin (insulin lispro);Supplemental insulin (insulin aspart);Long acting basal insulin (insulin detemir);Long acting basal insulin (insulin glargine)
22 Phase IV Study to Compare the Accuracy and Precission of Five Different Home Glucose Monitors;Optium Xceed, Contour Ts, Accu-chek Go, One Touch Select and Ez Smart Completed NCT01013402 Phase 4 Human insulin;Human Insulin
23 A Randomised, Parallel-group, Open-label, Multinational Trial Comparing the Safety and Efficacy of Insulin Aspart (NovoRapid®) Versus Human Insulin (Actrapid®), Used in a Multiple Injection Regimen, in the Treatment of Pregnant Women With Type 1 Diabetes, Focusing on Maternal Hypoglycaemia and Pregnancy Outcomes Completed NCT00365170 Phase 4 human insulin;insulin aspart
24 Liraglutide in Type 1 Diabetes. A Randomised, Double-blind, Placebo Controlled Study of the Effect of Liraglutide as an Additional Treatment to Insulin on HbA1c, Body Weight and Hypoglycaemia in Poorly Regulated Type 1 Diabetes Patients Completed NCT01612468 Phase 4 Liraglutide;Placebo
25 The Late Effects of Ethanol Intake on the Glucose Response to Subcutaneous Glucagon in Type 1 Diabetes Completed NCT02881060 Phase 4
26 Treatment of Hypoglycemia Following Gastric Bypass Surgery Completed NCT02527993 Phase 4 Glucobay (acarbose);Januvia (sitagliptin);Verapamil HEXAL (verapamil);Victoza (liraglutide);Signifor (pasireotide)
27 The Effect of Glucomannan Soluble Fiber on Glucose Homeostasis in Patients With RNY Gastric Bypass Surgery Completed NCT02336438 Phase 4
28 Treatment With Sitagliptin Phosphate in Patients With Reactive Hypoglycemia Secondary to Dysinsulinism. A Controlled, Randomized, Double-blind, Clinical Trial Completed NCT00847080 Phase 4 Sitagliptin phosphate;Placebo
29 Effect of Ciprofloxacin Versus Levofloxacin on QTc-interval and Dysglycemia in Diabetic and Non-Diabetic Patients. Completed NCT04456712 Phase 4 Ciprofloxacin 400 MG/200 ML Intravenous Solution;Levofloxacin 750 MG
30 A Comparison of Insulin Lispro MM Intensive Mixture Therapy With Progressive Dose-Titration of Insulin Lispro LM or Biphasic Insulin Aspart 30/70 Completed NCT00393705 Phase 4 Insulin Biphasic Aspart 30/70;insulin lispro LM;insulin lispro MM;insulin lispro LM
31 Effect of Lixisenatide on Glucagon Secretion During Hypoglycemia in Patients With Insulin-treated Type 2 Diabetes Completed NCT02020629 Phase 4 Lixisenatide
32 The Effect of Exenatide Compared to Lantus Insulin on Vascular Function Before and After a Meal Tolerance Test in Patients With Type 2 Diabetes Completed NCT00353834 Phase 4 Exenatide;Glargine Insulin
33 Sitagliptin for the Prevention and Treatment of Hyperglycemia in Patients With Type 2 Diabetes Undergoing Cardiac Surgery Completed NCT02556918 Phase 4 Sitagliptin;Placebo;Regular Human Insulin;Insulin glargine;Supplemental insulin (Insulin lispro);Supplemental insulin (Insulin aspart)
34 Metabolic Studies in Type 1 Diabetic Patients After Allogenic Intraportal Islet Transplantation. Completed NCT01668485 Phase 4
35 Acute Effects of Sodium-glucose Cotransporter-2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes Completed NCT04193566 Phase 4 Forxiga
36 A Multicenter, Prospective, Randomized, Open-label, Parallel Group Study to Investigate the Clinical Benefit on Hypoglycemia Frequency of 24 Weeks Treatment With Galvus Versus Usual Care (Any OAD of Another Class Added to Metformin Within SmPc) in Older Patients With Type 2 Diabetes Insufficiently Controlled by Metformin Monotherapy. Completed NCT01238978 Phase 4 Vildagliptin;"Usual Care"
37 An Open-Label, Randomized Naturalistic Study to Evaluate the Incidence of Hypoglycemia Comparing Sitagliptin With Sulfonylurea Treatment in Patients With Type 2 Diabetes During Ramadan Fasting Completed NCT01131182 Phase 4 Sitagliptin phosphate;Comparator: Sulfonylurea;Metformin
38 NEONATAL HYPOGLYCEMIA and CONTINUOUS GLUCOSE MONITORING: A RANDOMIZED CONTROLLED TRIAL IN PRETERM INFANTS Completed NCT02583776 Phase 4
39 The Incidence of Hypoglycemia in Insulin Glargine-Treated Subjects With Diabetes Mellitus Upon Switching Between Bedtime and Morning Dosing Completed NCT00609895 Phase 4 INSULIN GLARGINE
40 Study of the Effect of Vildagliptin on Glucagon Counterregulation Response During Hypoglycemia in Patients With Type 1 Diabetes Completed NCT01147276 Phase 4 Vildagliptin
41 Study of the Effect of Vildagliptin on Glucagon Counterregulation Response During Hypoglycemia in Insulin-treated Patients With Type 2 Diabetes Completed NCT01219400 Phase 4 Vildagliptin
42 Target Glycemic Control and the Incidence of Documented Symptomatic Hypoglycemia in Insulin naïve Subjects With Type 2 Diabetes Failing on Oral Hypoglycemic Agent(s) and Treated With Insulin Glargine or Insulin Detemir. Completed NCT00405418 Phase 4 Insulin glargine;Insulin Detemir
43 The Effect of Sitagliptin on Glucagon Counterregulation and Incretin Hormones During Mild Hypoglycemia in Elderly Patients With Metformin-treated Type 2 Diabetes Completed NCT02256189 Phase 4 Sitagliptin;Placebo
44 Glucagon Efficiency After High and Low Carbohydrate Diet Completed NCT02578498 Phase 4
45 Bedtime Insulin Glargine or Bedtime Neutral Protamine Lispro Combined With Sulfonylurea and Metformin in Type 2 Diabetes. A Randomized, Controlled Trial Completed NCT00641407 Phase 4 NPL insulin;Insulin glargine
46 Prevention of Hypoglycemia Among Diabetes Patients Admitted to Internal Medicine Departments, by Means of a Designated Nutritional Care Program Recruiting NCT03802942 Phase 4
47 A Randomized Cross-over Trial Evaluating Automated Insulin Delivery Technologies on Hypoglycemia and Quality of Life in Elderly Adults With Type 1 Diabetes Recruiting NCT04016662 Phase 4
48 The Effect of Long- and Intermediate-acting Insulins on Glycemic Control and Risk of Hypoglycemia Among Toddlers and Preschool Children With Newly Onset Type 1 Diabetes Mellitus: A Randomized Three Armed Trial Recruiting NCT04664764 Phase 4 Degludec;Glargine;NPH insulin
49 Use of Oral Antidiabetic Agents in Hospitalized Patients With Diabetes Recruiting NCT04416269 Phase 4 Oral Anti-diabetes Drugs alone;Basal bolus insulin;Supplemental insulin
50 Glucose Control During Labour in Gestational Diabetes Mellitus With Insulin Treatment: Insulin-Glucose-Infusion Versus Observational Approach - Is There a Difference in Neonatal Hypoglycemia Rate? Recruiting NCT02590016 Phase 4 Insulin, Aspart

Search NIH Clinical Center for Hypoglycemia

Inferred drug relations via UMLS 71 / NDF-RT 51 :


DEXTROSE 100% PWDR
Diazoxide
Glucagon
Glucose
GLUCOSE LIQUID

Cochrane evidence based reviews: hypoglycemia

Genetic Tests for Hypoglycemia

Genetic tests related to Hypoglycemia:

# Genetic test Affiliating Genes
1 Hypoglycemia 29

Anatomical Context for Hypoglycemia

MalaCards organs/tissues related to Hypoglycemia:

40
Pancreas, Pituitary, Liver, Hypothalamus, Cortex, Pancreatic Islet, Endothelial

Publications for Hypoglycemia

Articles related to Hypoglycemia:

(show top 50) (show all 40489)
# Title Authors PMID Year
1
Hypoglycemia in Older People With Type 2 Diabetes: Prevention and Treatment Strategies for Outpatient and Long-Term Care Facility Settings. 42 61
33509335 2021
2
Gla-100 Development: a Story of 'Serendipitous' Disruptive Innovation. 61 42
33247658 2020
3
Adoption of Gla-100 in India and its Impact on Insulin Usage Patterns. 42
33247660 2020
4
IGF2 over-expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting. 54 61
20527023 2010
5
[A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)]. 61 54
20519186 2010
6
Prolonged survival and improved glycemia in BioBreeding diabetic rats after early sustained exposure to glucagon-like peptide 1. 54 61
20527046 2010
7
Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension. 54 61
20200307 2010
8
Diazoxide-responsive hyperinsulinemic hypoglycemia caused by HNF4A gene mutations. 54 61
20164212 2010
9
Glucose transporter type 1 deficiency: ketogenic diet in three patients with atypical phenotype. 61 54
19515520 2010
10
Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. 61 54
20463416 2010
11
Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. 54 61
20380655 2010
12
A case of a giant phyllodes tumor of the breast with hypoglycemia caused by high-molecular-weight insulin-like growth factor II. 61 54
19259766 2010
13
Transient salt wasting in POMC-deficiency due to infection induced stress. 61 54
19998238 2010
14
Brain glucosamine boosts protective glucoprivic feeding. 54 61
20179264 2010
15
Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. 54 61
20206728 2010
16
Solitary fibrous tumor of soft tissue: a case report and immunohistochemical study. 54 61
20340008 2010
17
Type B insulin resistance syndrome with systemic lupus erythematosus. 61 54
20129024 2010
18
A novel mutation in the glycogen synthase 2 gene in a child with glycogen storage disease type 0. 54 61
20051115 2010
19
[Late onset 3-HMG-CoA lyase deficiency: a rare but treatable disorder]. 54 61
19932602 2010
20
Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs. 61 54
20107298 2010
21
Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes. 61 54
20107301 2010
22
Hypoglycemia due to ectopic secretion of insulin-like growth factor-I in a patient with an isolated sarcoidosis of the spleen. 61 54
20081321 2010
23
In vivo phosphoenolpyruvate carboxykinase promoter mapping identifies disrupted hormonal synergism as a target of inflammation during sepsis in mice. 54 61
19821526 2009
24
Novel FBP1 gene mutations in Arab patients with fructose-1,6-bisphosphatase deficiency. 61 54
19259699 2009
25
Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists. 61 54
19925391 2009
26
Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes. 54 61
19707744 2009
27
Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. 61 54
19790256 2009
28
Hyperinsulinaemic hypoglycaemia associated with a heterozygous missense mutation of R1174W in the insulin receptor (IR) gene. 61 54
19170714 2009
29
DPP-4 inhibitors in clinical practice. 61 54
19940419 2009
30
New therapies for diabesity. 54 61
19793506 2009
31
Treatment of dwarfism with recombinant human insulin-like growth factor-1. 54 61
19946434 2009
32
Malignant solitary fibrous tumor: report of 3 cases with unusual features. 54 61
19349855 2009
33
No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects. 54 61
19094067 2009
34
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. 61 54
19801361 2009
35
Hypoglycemia with intensive insulin therapy in critically ill patients: predisposing factors and association with mortality. 54 61
19623047 2009
36
Beta-human chorionic gonadotropin production associated with phyllodes tumor of the breast: an unusual paraneoplastic phenomenon. 61 54
19624411 2009
37
Selecting among ADA/EASD tier 1 and tier 2 treatment options. 61 54
19744422 2009
38
Defining the importance of daily glycemic control and implications for type 2 diabetes management. 61 54
19820277 2009
39
Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. 54 61
19638470 2009
40
Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans. 61 54
19470629 2009
41
Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists. 54 61
19624785 2009
42
[Diagnosis of glycogen storage disease type IIIA by detecting glycogen debranching enzyme activity, glycogen content and structure in muscle]. 54 61
19951495 2009
43
Hemangiopericytoma-associated hypoglycemia improved by glucocorticoid therapy: a case report. 61 54
19387873 2009
44
Delay in blood glucose monitoring during an insulin infusion protocol is associated with increased risk of hypoglycemia in intensive care units. 61 54
19670374 2009
45
Expression of insulin-like growth factor 2 in mesenchymal neoplasms. 54 61
19407853 2009
46
Lys169 of human glucokinase is a determinant for glucose phosphorylation: implication for the atomic mechanism of glucokinase catalysis. 61 54
19617908 2009
47
Factors determining inadequate hypoglycaemia during insulin tolerance testing (ITT) after pituitary surgery. 54 61
19178524 2009
48
3-Hydroxyacyl-coenzyme A dehydrogenase deficiency and hyperinsulinemic hypoglycemia: characterization of a novel mutation and severe dietary protein sensitivity. 61 54
19417036 2009
49
Hypoglycemia from IGF2 overexpression associated with activation of fetal promoters and loss of imprinting in a metastatic hemangiopericytoma. 61 54
19383775 2009
50
[A case of retroperitoneal solitary fibrous tumor associated with hypoglycemia]. 61 54
19673425 2009

Variations for Hypoglycemia

ClinVar genetic disease variations for Hypoglycemia:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 G6PC1 NM_000151.4(G6PC1):c.247C>T (p.Arg83Cys) SNV Pathogenic 11998 rs1801175 17:41055964-41055964 17:42903947-42903947
2 ABCC8 NM_000352.6(ABCC8):c.1024G>T (p.Gly342Trp) SNV Likely pathogenic 523360 rs763028380 11:17474818-17474818 11:17453271-17453271
3 ABCC8 NM_000352.6(ABCC8):c.1793G>A (p.Arg598Gln) SNV Likely pathogenic 523361 rs1344172059 11:17452385-17452385 11:17430838-17430838
4 ABCC8 NM_000352.6(ABCC8):c.3517G>A (p.Val1173Met) SNV Likely pathogenic 35609 rs141322087 11:17426099-17426099 11:17404552-17404552
5 KCNJ11 NM_000525.3(KCNJ11):c.185C>G (p.Thr62Arg) SNV Likely pathogenic 373928 rs1057518775 11:17409454-17409454 11:17387907-17387907
6 MYOM1 NM_003803.4(MYOM1):c.3260G>A (p.Trp1087Ter) SNV Likely pathogenic 804425 rs374670754 18:3116372-3116372 18:3116374-3116374
7 SCN1A-AS1 NM_001365536.1(SCN9A):c.1997A>G (p.Lys666Arg) SNV Uncertain significance 6367 rs121908919 2:167138296-167138296 2:166281786-166281786

Expression for Hypoglycemia

Search GEO for disease gene expression data for Hypoglycemia.

Pathways for Hypoglycemia

Pathways related to Hypoglycemia according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 SLC25A20 SLC16A1 KCNJ11 INS HADH GYS2
2
Show member pathways
12.89 INSR INS IGF2 GYS2 G6PC1 AKT2
3
Show member pathways
12.81 INSR INS GYS2 GCK G6PC1 FBP1
4
Show member pathways
12.8 SLC25A20 HADH ACADVL ACADM ACADL
5
Show member pathways
12.79 KCNJ11 INS GCK GCG CRH ABCC8
6 12.66 INSR INS IGF2 GCK AKT2
7 12.44 INSR INS GLUD1 GCG FBP1 AKT2
8
Show member pathways
12.42 INSR INS GYS2 G6PC1 FBP1 AKT2
9
Show member pathways
12.37 HADH ACADVL ACADM ACADL
10
Show member pathways
12.34 INSR INS GYS2 G6PC1 FBP1 AKT2
11
Show member pathways
12.26 KCNJ11 INS GCG ABCC8
12
Show member pathways
12.1 INSR INS GYS2 AKT2
13
Show member pathways
11.97 INSR INS G6PC1 AKT2
14 11.88 INSR G6PC1 AKT2
15 11.85 INSR INS AKT2
16
Show member pathways
11.81 INSR INS GYS2 G6PC1 AKT2
17
Show member pathways
11.8 INS GCK AKT2
18 11.75 HADH GLUD1 ACADM
19
Show member pathways
11.64 KCNJ11 INSR INS GCK ABCC8
20
Show member pathways
11.63 HADH ACADVL ACADM ACADL
21 11.52 INSR INS AKT2
22 11.46 GYS2 GCK GCG G6PC1 FBP1 AKT2
23 11.45 KCNJ11 GYS2 AKT2 ABCC8
24 11.37 INSR INS AKT2
25
Show member pathways
11.28 SLC25A20 HADH ACADVL ACADM ACADL
26 11.16 INSR INS AKT2
27 10.87 KCNJ11 INS HADH GCK G6PC1 ACADVL
28
Show member pathways
10.84 INSR AKT2
29
Show member pathways
10.61 HADH ACADM

GO Terms for Hypoglycemia

Cellular components related to Hypoglycemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrial matrix GO:0005759 9.55 HADH GLUD1 ACADVL ACADM ACADL
2 mitochondrion GO:0005739 9.28 SLC25A20 KCNJ11 HADH GLUD1 GCK ACADVL
3 inward rectifying potassium channel GO:0008282 8.96 KCNJ11 ABCC8

Biological processes related to Hypoglycemia according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 10.04 SLC16A1 HADH ACADVL ACADM ACADL
2 positive regulation of cell proliferation GO:0008284 10 INSR INS IGF2 CRH AKT2
3 response to drug GO:0042493 9.93 KCNJ11 HADH CRH ABCC8
4 positive regulation of protein phosphorylation GO:0001934 9.88 INSR IGF2 CRH AKT2
5 fatty acid metabolic process GO:0006631 9.85 HADH ACADVL ACADM ACADL
6 carbohydrate metabolic process GO:0005975 9.8 INSR INS IGF2 GCK FBP1 AKT2
7 cellular response to insulin stimulus GO:0032869 9.78 INSR GCK G6PC1 AKT2
8 response to insulin GO:0032868 9.77 HADH G6PC1 ABCC8
9 insulin receptor signaling pathway GO:0008286 9.73 INSR INS IGF2 AKT2
10 positive regulation of glucose import GO:0046326 9.71 INSR INS AKT2
11 negative regulation of insulin secretion GO:0046676 9.69 KCNJ11 HADH ABCC8
12 positive regulation of mitotic nuclear division GO:0045840 9.67 INSR INS IGF2
13 fatty acid beta-oxidation GO:0006635 9.67 HADH ACADVL ACADM ACADL
14 negative regulation of gluconeogenesis GO:0045721 9.65 INS GCK
15 positive regulation of calcium ion import GO:0090280 9.65 GCG CRH
16 glucose metabolic process GO:0006006 9.65 KCNJ11 INS IGF2 GCK AKT2
17 negative regulation of fatty acid biosynthetic process GO:0045717 9.64 ACADVL ACADL
18 inorganic cation transmembrane transport GO:0098662 9.63 KCNJ11 ABCC8
19 glycogen biosynthetic process GO:0005978 9.63 GYS2 AKT2 ACADM
20 glucose homeostasis GO:0042593 9.63 SLC16A1 INSR INS GCK GCG G6PC1
21 protein kinase A signaling GO:0010737 9.62 MYOM1 GCG
22 regulation of gluconeogenesis GO:0006111 9.62 FBP1 ACADM
23 regulation of cholesterol metabolic process GO:0090181 9.61 ACADVL ACADL
24 neuron projection maintenance GO:1990535 9.59 INSR INS
25 glucose 6-phosphate metabolic process GO:0051156 9.58 GCK G6PC1
26 fatty acid beta-oxidation using acyl-CoA dehydrogenase GO:0033539 9.58 ACADVL ACADM ACADL
27 positive regulation of respiratory burst GO:0060267 9.57 INSR INS
28 negative regulation of fatty acid oxidation GO:0046322 9.56 ACADVL ACADL
29 carnitine metabolic process, CoA-linked GO:0019254 9.52 ACADM ACADL
30 regulation of insulin secretion GO:0050796 9.43 SLC16A1 KCNJ11 HADH GCK GCG ABCC8
31 positive regulation of glycogen biosynthetic process GO:0045725 9.02 INSR INS IGF2 GCK AKT2

Molecular functions related to Hypoglycemia according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.89 HADH GLUD1 ACADVL ACADM ACADL
2 hormone activity GO:0005179 9.62 INS IGF2 GCG CRH
3 flavin adenine dinucleotide binding GO:0050660 9.61 ACADVL ACADM ACADL
4 NAD+ binding GO:0070403 9.48 HADH GLUD1
5 cation-transporting ATPase activity GO:0019829 9.46 KCNJ11 ABCC8
6 oxidoreductase activity, acting on the CH-CH group of donors GO:0016627 9.43 ACADVL ACADM ACADL
7 ATP-activated inward rectifier potassium channel activity GO:0015272 9.4 KCNJ11 ABCC8
8 long-chain-acyl-CoA dehydrogenase activity GO:0004466 9.37 ACADVL ACADL
9 identical protein binding GO:0042802 9.36 SLC16A1 MYOM1 INSR INS HADH GLUD1
10 insulin-like growth factor receptor binding GO:0005159 9.33 INSR INS IGF2
11 acyl-CoA dehydrogenase activity GO:0003995 9.13 ACADVL ACADM ACADL

Sources for Hypoglycemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....